The Expert Committee recommended the inclusion of cabergoline on the core list of the EML for the medical management of hyperprolactinaemia associated with prolactin-secreting pituitary adenomas (prolactinomas). Listing was recommended with bromocriptine as a therapeutic alternative under a square box listing. Overall, the Committee considered that the available evidence suggests medical therapy with dopamine agonists can achieve prolactin normalization in most patients. The Committee noted that dopamine agonist therapy is a preferred first-line intervention for management of hyperprolactinaemia and prolactinomas and may be the only option in settings where specialist neurosurgery is not available, or in patients for whom surgery is not feasible. Listing was recommended with bromocriptine as therapeutic alternative under a square box listing. Cabergoline may be superior to bromocriptine in decreasing the serum prolactin concentration and has fewer adverse effects but is usually more costly.